Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
41.53
+1.68 (4.22%)
At close: May 12, 2025, 4:00 PM
42.27
+0.74 (1.78%)
After-hours: May 12, 2025, 5:46 PM EDT

Akero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
39.9437.9331.0729.8719.1315.27
Upgrade
Research & Development
266.41247.5141.885.2881.7664.88
Upgrade
Operating Expenses
306.35285.42172.87115.16100.8980.15
Upgrade
Operating Income
-306.35-285.42-172.87-115.16-100.89-80.15
Upgrade
Interest Expense
-4.83-4.67-3.1-0.74--
Upgrade
Interest & Investment Income
41.7438.0324.213.860.110.95
Upgrade
EBT Excluding Unusual Items
-269.44-252.06-151.76-112.03-100.78-79.21
Upgrade
Pretax Income
-269.44-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income
-269.44-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income to Common
-269.44-252.06-151.76-112.03-100.78-79.21
Upgrade
Shares Outstanding (Basic)
726753393531
Upgrade
Shares Outstanding (Diluted)
726753393531
Upgrade
Shares Change (YoY)
29.31%27.71%34.84%11.94%10.69%108.77%
Upgrade
EPS (Basic)
-3.74-3.75-2.89-2.87-2.89-2.52
Upgrade
EPS (Diluted)
-3.74-3.75-2.89-2.87-2.89-2.52
Upgrade
Free Cash Flow
--231.11-145.37-92.52-79.68-70.95
Upgrade
Free Cash Flow Per Share
--3.44-2.77-2.37-2.29-2.25
Upgrade
EBITDA
-306.33-285.41-172.84-115.11-100.85-80.14
Upgrade
D&A For EBITDA
0.020.020.030.040.040.02
Upgrade
EBIT
-306.35-285.42-172.87-115.16-100.89-80.15
Upgrade
Updated May 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q